不同药物治疗EGFR-TKI耐药后晚期NSCLC的临床效果研究  

Clinical Effects of Different Drugs on Advanced NSCLC After Egfr-Tki Resistance

作　　者：顾艺难[1] 秦少云 GU Yinan;QIN Shaoyun(Department of Respiratory Medicine,Taizhou People's Hospital,Taizhou Jiangsu 225300,China)

机构地区：[1]泰州市人民医院呼吸内科

出　　处：《中国继续医学教育》2019年第28期136-138,共3页China Continuing Medical Education

摘　　要：目的分析培美曲塞联合吉非替尼应用于EGFR-TKI耐药后晚期非小细胞肺癌患者的临床疗效。方法选取2013年8月—2018年1月期间,于本院接收的EGFR-TKI耐药后晚期非小细胞肺癌患者120例,以随机方式分为参照组与研究组,各60例,参照组以单药培美曲塞进行治疗,研究组采用培美曲塞与吉非替尼联合治疗,对两组患者治疗后的临床缓解率、生存率以及不良反应情况进行对比分析。结果治疗后,研究组的床缓解率分别为43.33%,参照组为25.00%,研究组患者临床缓解率明显高于参照组,P<0.05;研究组患者1年生存率56.67%均明显高于参照组的38.33%,P<0.05;且研究组患者的不良反应发生率3.33%与参照组的20.00%,P<0.05,差异有统计学意义。结论对EGFR-TKI耐药后的晚期非小细胞肺癌患者采用培美曲塞与吉非替尼联合治疗效果显著,可有效延长患者的生存期,且安全性较高。Objective To analyze the clinical efficacy of pemetrexed combined with gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) after EGFR-TKI resistance.Methods Selection during August 2013 to January 2018,in our hospital to receive EGFR - TKI resistance after 120 cases of advanced non-small cell lung cancer patients,divided into control group and the team in a random way,each 60 cases,control group treated with single drug pemetrexed,team with pemetrexed the treatment with combined treatment,the clinical remission rate of two groups of patients after treatment,the survival rate and adverse reactions were analyzed.Result After treatment,the bed remission rate of the study group was 43.33% and that of the reference group was 25.00%, respectively.The clinical remission rate of the study group was significantly higher than that of the reference group (P < 0.05).The 1-year survival rate of patients in the study group was significantly higher than that in the control group (38.33%,P < 0.05).The incidence of adverse reactions was 3.33% in the study group and 20.00% in the control group,P < 0.05, indicating a significant difference.Conclusion Pemetrexed combined with gefitinib is effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with EGFR-TKI resistance.It can effectively prolong the survival time of patients,and has high safety.

关 键 词：培美曲塞 吉非替尼 EGFR-TKI 晚期非小细胞肺癌 治疗 疗效 

分 类 号：R734[医药卫生—肿瘤]